


WHAT IS CLAIMED IS:

1. A compound of formula I:



5 wherein,

R5, R1a and R1 independently are hydrogen, C1-6 alkyl, halo, C1-6 alkoxy, C3-10 cycloalkyl, C6-10 aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of Ra;

10

R2 is hydrogen, C1-6 alkyl, and C3-10 cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO2, N, or NR2a and optionally substituted by 1-3 Ra groups;

15

R2a is hydrogen, and C1-6 alkyl;

20

R3 and R3a are independently hydrogen, halo, C1-6 alkyl, C3-10 cycloalkyl, and C6-10 aryl, said aryl and alkyl optionally substituted with 1-3 groups of Ra; or

25

R3 and R3a taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO2, N, or NR2a and optionally substituted by 1-3 Ra groups;

R4 is hydrogen, halo, C1-6 alkyl, and trihaloalkyl;

30

Ra represents C1-6 alkoxy, C1-6 alkyl, CF3, nitro, amino, cyano, C1-6 alkylamino, or halogen; and

n represents 1-3;

or a pharmaceutically acceptable salt, enantiomer, or diasteriomer thereof.

5 2. A compound according to claim 1 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl .

10 3. A compound according to claim 1 wherein R² is hydrogen or C₁₋₄ alkyl, and n is 1.

15 4. A compound according to claim 1 wherein R^{1a} and R¹ independently are hydrogen, tert-butyl, 1,2,2-trichlorovinyl, or phenyl; R² is hydrogen or C₁₋₄ alkyl, and n is 1.

20 5. A compound according to claim 4 wherein R^{1a} and R¹ are tert-butyl, and R² is hydrogen.

25 6. A compound which is:

- 2-aminomethyl-5-tert-butyl-3-phenylphenol,
- 20 2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
- 3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
- 3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
- 3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
- 25 3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
- 2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
- 3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
- 30 3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
- tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
- 3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
- 3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
- 35 3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,


3,5-Di-*tert*-butyl-2-[1-(ethylamino)ethyl]phenol,
 3,5-Di-*tert*-butyl-2-[(propylamino)methyl]phenol,
 3,5-Di-*tert*-butyl-2-{{(pyrazin-2-ylmethyl)amino}methyl}phenol,
 2-(aminomethyl)-3,5-di-*tert*-butylphenol hydrochloride,
 5 2-Aminomethyl-5-*tert*-butylphenol hydrochloride,
 or pharmaceutically acceptable salts thereof.

7. A composition comprising a compound of claim 1 and a pharmaceutically acceptable salt thereof.

10

8. A composition comprising a compound of claim 6 and a pharmaceutically acceptable salt thereof.

9. A method for the treatment of malaria which comprises
 15 administering to a patient in need of such treatment a compound of formula I:



wherein,

20 R5, R1a and R1 independently are hydrogen, C1-6 alkyl, halo, C1-6 alkoxy, C3-10 cycloalkyl, C6-10 aryl, and trihalovinyl, said aryl optionally substituted with 1-3 groups of Ra;

25 R2 is hydrogen, C1-6 alkyl, and C3-10 cycloalkyl; taken together with any intervening atoms can form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO2, N, or NR2a and optionally substituted by 1-3 Ra groups;

30 R2a is hydrogen, and C1-6 alkyl;